Kerri Fitzgerald

DocwireNews

The U.S. Food and Drug Administration approved Jelmyto&trade; (mitomycin gel) to treat low-grade upper tract <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/drug-overcomes-chemotherapy-resistance-in-ovarian-cancer-study-shows/">urothelial cancer</a> (UTUC), making it the first non-surgical treatment for this indication.The decision was based on results of the single-arm, phase III ongoing OLYMPUS trial that included 71 patients with low-grade UTUC who had never undergone treatment or had recurrent low-grade non-invasive <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-approves-first-new-bladder-cancer-treatment-in-20-years/">UTUC</a> with at least one measurable papillary tumor. Patients received mitomycin gel at the recommended dose of 4 mg/mL weekly for six weeks. If they had a complete response (CR), patients could continue treatment for up to 11 additional months.<h2>Complete response observed in more than half of patients</h2>More than half of patients (n=41; 58%) had a CR (primary endpoint) following six treatments of mitomycin gel. Nineteen of these patients (46%) continued to have a CR at 12 months. Median duration of CR was not reached.The most common adverse events (AEs) associated with mitomycin gel are ureteric obstruction, flank pain, urinary tract infection, hematuria, renal dysfunction, fatigue, nausea, abdominal pain, dysuria, and vomiting. AEs resulted in 23% of patients discontinuing treatment and 34% having dose interruptions.Patients with ureteric obstruction may require transient or long-term stents to relieve this obstruction. The obstruction may be persistent and did not resolve or did not resolve completely in 51% of patients who experienced obstruction due to mitomycin gel. Patients with a glomerular filtration rate of less than 30 mL/min should not receive mitomycin gel.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

FDA Approves First Non-Surgical Treatment for Low-Grade Upper Tract Urothelial Cancer

Oncology

The U.S. Food and Drug Administration approved Jelmyto™ (mitomycin gel) to treat low-grade upper tract urothelial cancer (UTUC), making it the first non-surgical treatment ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe